ArticleAnnals of the rheumatic diseases2020
SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment.
Article in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Multi-omics analysis uncovered systemic lupus erythematosus and COVID-19 crosstalk.Molecular medicine (Cambridge, Mass.) · 2024Article
- Patients with lupus are not protected from COVID-19.Annals of the rheumatic diseases · 2021Article
- Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation.Journal of thrombosis and thrombolysis · 2021Review
- Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.Annals of the rheumatic diseases · 2020Article
- COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients.Seminars in arthritis and rheumatism · 2020Article
- SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus.The American journal of case reports · 2020Article
- Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19.Expert review of clinical immunology · 2020Review
- Initial data from the COVID-19 Global Rheumatology Alliance provider registries - Authors' reply.The Lancet. Rheumatology · 2020Article
- Initial data from the COVID-19 Global Rheumatology Alliance provider registries.The Lancet. Rheumatology · 2020Article
- COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia.Case reports in infectious diseases · 2020Article
- Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review.Frontiers in pharmacology · 2020Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32295787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.